<link>https://www.fool.com</link><width>144</width><height>34</height></image><item><title>Grail's Slump Enters Week 10. Is There Any End in Sight?</h1> <article> <h1>Grail's Slump Enters Week 10. Is There Any End in Sight?</h1> <p>newsfeedback@fool.com (Lee Samaha) — Mon, 25 May 2026 08:00:00 -0400</p> <p><strong>Grail</strong>'s <span class="ticker" data-id="545523">(NASDAQ: GRAL)</span> share price decline of over 20% so far in 2026 is understandable. After all, when a multicancer early detection (MCED) test company misses a primary endpoint of a landmark three-year trial, investors immediately price in difficulties receiving Food and Drug Administration (FDA) approval, let alone receiving insurance coverage for a test that failed in a trial. That said, there's still a powerful case for the stock, and a very strong catalyst could be about to be unleashed, propelling it higher.</p><p>The investment case for the stock centers on its MCED test, Galleri, which completed a three-year, 142,000-person trial with England's National Health Service (NHS). Grail released the top-line results from the trial in mid-February and promptly disappointed the market by revealing it had missed its primary endpoint.</p><p>Early-stage cancers (Stage I and Stage II) are far easier and cheaper to treat than later-stage <a href="https://www.fool.com/investing/stock-market/market-sectors/healthcare/cancer-stocks/">cancers</a> (Stage III and Stage IV). The latter two are defined by cancer that has spread to surrounding tissues (Stage III) or to another organ (Stage IV). </p><p><a href="https://www.fool.com/investing/2026/05/25/grails-slump-enters-week-10-is-there-any-end-in-si/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>Why 1 Wall Street Analyst Thinks Pfizer (PFE) Stock Could Soar 38%</h1> <p>newsfeedback@fool.com (Selena Maranjian) — Mon, 25 May 2026 05:45:00 -0400</p> <p>If you've spent any time reading about certain stocks, you'll have noticed that opinions among Wall Street analysts can vary widely. Because there's no way to definitively determine where a stock will be in the future, it's hard to know for sure that it's a buy, sell, or hold. It's the same with The Motley Fool: One of its writers might be very bullish on one stock, while her colleague is bearish. That's why it's good to read multiple opinions and think them through on your own.</p><p>Here's one example: <strong>Pfizer</strong> <span class="ticker" data-id="204972">(NYSE: PFE)</span>. The MarketWatch website recently tracked 28 ratings for the stock: Nine Wall Street analysts said "buy," one said the stock was overweight (which essentially means it's a buy), 15 said "hold," and three said "sell." The consensus, then, was to hold.</p><p>These ratings are occasionally changed or reaffirmed. Guggenheim Securities recently reaffirmed its buy rating for Pfizer, along with a price target of $36 per share. That's fully 38% higher than the recent share price of about $26.</p><p><a href="https://www.fool.com/investing/2026/05/25/why-1-wall-street-analyst-thinks-pfizer-pfe-stock/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>Eli Lilly Just Made a Game-Changing Move in the Billion-Dollar Weight Loss Drug Space. Here's What You Need to Know.</h1> <p>newsfeedback@fool.com (Adria Cimino) — Mon, 25 May 2026 05:05:00 -0400</p> <p>When you think of growth stocks, you may immediately think of technology. But this isn't the only field delivering significant revenue gains these days. In fact, you'll find one of the biggest growth themes in a surprising area: healthcare. I'm talking about the business of weight loss drugs. Today, <strong>Eli Lilly</strong> <span class="ticker" data-id="204336">(NYSE: LLY)</span> and <strong>Novo Nordisk</strong> lead this market, marching toward a value of $100 billion by early next decade. And others, from biotech <strong>Viking Therapeutics</strong> to pharma giant <strong>Pfizer</strong>, aim to eventually participate too.</p><p>So this market offers high growth -- but eventually competition may heat up as new drugs reach the finish line. This means it's crucial for players to continue building out their portfolios. With this in mind, Lilly just made a game-changing move in this high-growth space. Here's what you need to know.</p><p class="caption">Image source: Getty Images.</p><p><a href="https://www.fool.com/investing/2026/05/25/eli-lilly-made-game-changing-move/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>Doximity Stock Just Got Crushed. Is This a Rare Chance to Buy a High-Quality Growth Company on Sale?</h1> <p>newsfeedback@fool.com (Josh Kohn-Lindquist) — Sun, 24 May 2026 12:30:00 -0400</p> <p>Shares of the leading digital platform for medical professionals, <strong>Doximity </strong><span class="ticker" data-id="344751">(NYSE: DOCS)</span>, dropped again earlier in May after the company reported <a href="https://www.fool.com/investing/2026/05/14/why-doximity-stock-plunged-today/">fourth-quarter earnings</a>, and the stock is now down a staggering 56% in 2026.</p><p>The big issue on the market's mind is whether the company can survive the threat that AI's rise may pose to Doximity's operations. For instance, the company's Scribe product, which transcribes and generates notes during doctor visits, is a somewhat "common" feature in today's AI-powered world.</p><p>Similarly, its Ask solution is a large language model tailored for doctors -- but may not offer enough differentiation from the leading AI companies today.</p><p><a href="https://www.fool.com/investing/2026/05/24/doximity-just-got-crushed-is-this-a-rare-chance/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>What's the Better Dividend Stock Today: AbbVie or Pfizer?</h1> <p>newsfeedback@fool.com (David Jagielski, CPA) — Sun, 24 May 2026 12:00:00 -0400</p> <p><strong>AbbVie </strong><span class="ticker" data-id="284305">(NYSE: ABBV)</span> and <strong>Pfizer </strong><span class="ticker" data-id="204972">(NYSE: PFE)</span> are two top healthcare stocks, and they're investments that can generate a ton of dividend income for your portfolio.</p><p>AbbVie, which yields 3.2%, has been a dividend growth beast for decades and has been doing a good job of growing its business even after its top-selling drug Humira lost patent protection. It has proven to be a good long-term dividend investment to hang on to.</p><p>Pfizer offers a higher yield of 6.7%, but it's a bit riskier, given that it's still in the midst of trying to get back to growth and is facing some daunting patent cliffs in the near future. For investors, the pressing issue is whether the business is on the right track and if its dividend is indeed safe.</p><p><a href="https://www.fool.com/investing/2026/05/24/whats-the-better-dividend-stock-abbvie-or-pfizer/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million</h1> <p>newsfeedback@fool.com (Jonathan Ponciano) — Sun, 24 May 2026 10:19:48 -0400</p> <p>Deep Track Capital disclosed a buy of 168,066 additional <strong>Structure Therapeutics</strong> <span class="ticker" data-id="482217">(NASDAQ:GPCR)</span> shares in its May 15, 2026, SEC filing, with an estimated transaction value of $11.50 million based on quarterly average pricing.</p><p>According to its <a href="https://www.sec.gov/Archives/edgar/data/1856083/000185608326000003/0001856083-26-000003-index.html">SEC filing</a> dated May 15, 2026, Deep Track Capital increased its position in Structure Therapeutics by 168,066 shares during the first quarter. The estimated transaction value was $11.50 million, calculated using the average closing price for the quarter. The quarter-end value of the stake decreased by $79.69 million, a change that includes both share purchases and stock price movement.</p><p>Structure Therapeutics is a clinical-stage biotechnology company headquartered in South San Francisco, California, with a focus on advancing novel oral therapeutics for chronic diseases. The company leverages expertise in GPCR-targeted drug discovery to address significant unmet needs in metabolic and pulmonary indications. Its pipeline and differentiated approach position it to compete in the evolving landscape of oral therapeutics for complex diseases.</p><p><a href="https://www.fool.com/coverage/filings/2026/05/24/this-biotech-is-up-60-a-top-healthcare-fund-just-bought-another-usd11-million/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter</h1> <p>newsfeedback@fool.com (Jonathan Ponciano) — Sun, 24 May 2026 10:13:59 -0400</p> <p>On May 15, 2026, Deep Track Capital disclosed a new position in <strong>Alumis</strong> <span class="ticker" data-id="550133">(NASDAQ:ALMS)</span>, acquiring 6,772,595 shares—an estimated $169.31 million trade based on quarterly average pricing.</p><p>According to a <a href="https://www.sec.gov/Archives/edgar/data/1856083/000185608326000003/0001856083-26-000003-index.html">May 15, 2026 SEC filing</a>, Deep Track Capital reported acquiring 6,772,595 shares of <strong>Alumis</strong> <span class="ticker" data-id="550133">(NASDAQ:ALMS)</span> during the first quarter of 2026. The estimated transaction value was $169.31 million, based on the period’s average unadjusted closing price. As of March 31, 2026, the fund’s Alumis stake was valued at $149.20 million, reflecting both the purchase and stock price changes during the quarter.</p><p>Alumis is a biotechnology company specializing in the development of novel therapies for autoimmune and neuroinflammatory conditions. It leverages expertise in allosteric TYK2 inhibition to advance a pipeline of differentiated clinical candidates. With a focus on unmet medical needs, Alumis aims to establish a competitive edge through innovative science and targeted clinical development strategies.</p><p><a href="https://www.fool.com/coverage/filings/2026/05/24/this-biotech-stock-is-up-355-one-fund-added-a-usd169-million-position-last-quarter/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>Looking to Buy Bristol Myers Squibb Stock on the Dip? Read This First.</h1> <p>newsfeedback@fool.com (Keith Speights) — Sun, 24 May 2026 05:50:00 -0400</p> <p><strong>Bristol Myers Squibb</strong>'s <span class="ticker" data-id="202977">(NYSE: BMY)</span> shares are rebounding after sinking roughly 11%. However, the big <a href="https://www.fool.com/investing/stock-market/market-sectors/healthcare/pharmaceutical-stocks/">pharma stock</a> remains below the early March year-to-date peak. With a forward price-to-earnings multiple of only 9.4, Bristol Myers Squibb may seem to be an attractive pick for value investors.</p><p>But numbers don't always tell the full story. Looking to buy Bristol Myers Squibb on the dip? There's something you need to know first.</p><p class="caption">Image source: Getty Images.</p><p><a href="https://www.fool.com/investing/2026/05/24/looking-to-buy-bristol-myers-squibb-stock-on-the-d/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge</h1> <p>newsfeedback@fool.com (Jonathan Ponciano) — Sat, 23 May 2026 18:20:03 -0400</p> <p>Superstring Capital Management cut its stake in <strong>UroGen Pharma Ltd. </strong><span class="ticker" data-id="339108">(NASDAQ:URGN)</span>, selling 330,983 shares in the first quarter in an estimated $6.64 million trade based on average quarterly pricing, according to a May 14, 2026, SEC filing.</p><p>According to a <a href="https://www.sec.gov/Archives/edgar/data/1931118/000193111826000008/0001931118-26-000008-index.html">filing with the Securities and Exchange Commission</a> dated May 14, 2026, Superstring Capital Management reduced its position in UroGen Pharma Ltd. by 330,983 shares. The estimated transaction value is $6.64 million, based on the average closing price for the quarter ended March 31, 2026. The quarter-end value of the position fell by $9.86 million, reflecting both share sales and price changes.</p><p>UroGen Pharma Ltd. is a biotechnology company focused on advancing innovative therapies for urothelial cancers, leveraging proprietary RTGel technology and a robust clinical pipeline. The company pursues a strategy of addressing unmet medical needs in specialty oncology markets, with a particular emphasis on non-muscle invasive bladder cancer. Its competitive edge lies in its differentiated delivery platform and strategic collaborations with leading pharmaceutical and research institutions.</p><p><a href="https://www.fool.com/coverage/filings/2026/05/23/what-to-know-about-this-fund-s-usd6-6-million-urogen-sale-after-a-600-stock-surge/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally</h1> <p>newsfeedback@fool.com (Jonathan Ponciano) — Sat, 23 May 2026 18:13:51 -0400</p> <p>Superstring Capital Management disclosed a new position in <strong>Vir Biotechnology</strong> <span class="ticker" data-id="341659">(NASDAQ:VIR)</span>, acquiring 730,548 shares in the first quarter. The estimated transaction value was $5.82 million based on quarterly average pricing.</p><p>According to a <a href="https://www.sec.gov/Archives/edgar/data/1931118/000193111826000008/0001931118-26-000008-index.html">filing with the U.S. Securities and Exchange Commission</a> dated May 14, 2026, Superstring Capital established a new position in Vir Biotechnology with 730,548 shares purchased. The estimated transaction value was $5.82 million, based on the mean unadjusted closing price for the first quarter of 2026. The fund’s quarter-end position in Vir Biotechnology was valued at $6.55 million, reflecting both trading activity and price appreciation.</p><p>Vir Biotechnology, Inc. is a commercial-stage biotechnology company specializing in the development of innovative immunology-based therapies for serious infectious diseases. The company leverages collaborations with leading global partners to advance its pipeline and expand market reach. Vir's strategy centers on addressing unmet medical needs through scientific innovation and strategic alliances in the healthcare sector.</p><p><a href="https://www.fool.com/coverage/filings/2026/05/23/why-a-biotech-fund-opened-a-new-usd6-million-position-in-vir-amid-a-99-stock-rally/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>Phibro's CEO transition puts this insider sale in context</h1> <p>newsfeedback@fool.com (Seena Hassouna) — Sat, 23 May 2026 17:07:00 -0400</p> <p>Jack Bendheim, President and CEO of <strong>Phibro Animal Health Corporation</strong> <span class="ticker" data-id="289019">(NASDAQ:PAHC)</span>, disclosed the indirect sale of 18,608 shares of Common Stock across multiple open-market transactions from May 5, 2026 through May 7, 2026, as reported in the <a href="https://www.sec.gov/Archives/edgar/data/1069899/000110465926057389/0001104659-26-057389-index.htm">SEC Form 4 filing</a>.</p><p><em>Transaction value based on SEC Form 4 weighted average purchase price ($54.61); post-transaction value based on total reported shares multiplied by the final May 7, 2026 close price, as calculated in SEC data.</em></p><p>* 1-year performance calculated using May 7th, 2026 as the reference date.</p><p><a href="https://www.fool.com/coverage/filings/2026/05/23/phibro-s-ceo-transition-puts-this-insider-sale-in-context/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>Is Viking Therapeutics a Top Takeover Target?</h1> <p>newsfeedback@fool.com (Jeff Siegel) — Sat, 23 May 2026 16:31:00 -0400</p> <p><strong>Viking Therapeutics</strong> <span class="ticker" data-id="335108">(NASDAQ: VKTX)</span> increasingly looks like an acquisition candidate in biotech. But why?</p><p>It's because<a href="https://www.fool.com/investing/stock-market/market-sectors/healthcare/pharmaceutical-stocks/"> large pharmaceutical companies</a> are desperate to secure obesity drug exposure, and Viking controls one of the more advanced independent GLP-1/GIP programs still available.</p><p>Its lead obesity candidate, VK2735, is currently being developed in both injectable and oral formulations. The company's Phase 3 VANQUISH obesity studies are already fully enrolled, while management expects to initiate Phase 3 trials for the oral tablet later this year. </p><p><a href="https://www.fool.com/investing/2026/05/23/is-viking-therapeutics-a-top-takeover-target/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch</h1> <p>newsfeedback@fool.com (Jonathan Ponciano) — Sat, 23 May 2026 16:28:41 -0400</p> <p>On May 15, 2026, Prosight Management disclosed a buy of 180,367 shares of <strong>Nektar Therapeutics</strong> <span class="ticker" data-id="204713">(NASDAQ:NKTR)</span>, an estimated $10.27 million trade based on quarterly average pricing.</p><p>According to a <a href="https://www.sec.gov/Archives/edgar/data/1617201/000142050626001036/0001420506-26-001036-index.html">Securities and Exchange Commission (SEC) filing</a> dated May 15, 2026, Prosight Management increased its position in Nektar Therapeutics by 180,367 shares. The estimated value of the additional shares is $10.27 million, calculated using the average closing price for the quarter ending March 31, 2026. The quarter-end value of the firm’s Nektar Therapeutics stake rose by $29.43 million, a figure that includes both trading activity and share price appreciation.</p><p>Nektar Therapeutics is a biotechnology company specializing in the development of novel therapeutics for oncology and immunology indications. The company leverages proprietary drug discovery platforms and strategic partnerships to advance a diverse clinical pipeline. Its focus on innovative biologics and collaborative R&D positions it to address significant unmet needs in the global healthcare market.</p><p><a href="https://www.fool.com/coverage/filings/2026/05/23/what-to-know-about-this-fund-s-usd10-million-nektar-bet-ahead-of-a-key-phase-3-launch/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>This Healthcare Investor Added $43 Million to a Genomics Leader Growing Volume 34%</h1> <p>newsfeedback@fool.com (Jonathan Ponciano) — Sat, 23 May 2026 16:17:22 -0400</p> <p>On May 15, 2026, Prosight Management disclosed a purchase of 468,463 shares of <strong>GeneDx Holdings</strong> <span class="ticker" data-id="345209">(NASDAQ:WGS)</span>, an estimated $42.72 million trade based on quarterly average pricing.</p><p>According to a <a href="https://www.sec.gov/Archives/edgar/data/1617201/000142050626001036/0001420506-26-001036-index.html">Securities and Exchange Commission (SEC) filing</a> dated May 15, 2026, Prosight Management increased its holdings in GeneDx Holdings by 468,463 shares. The estimated transaction value, based on the average unadjusted closing price for the first quarter of 2026, was $42.72 million. The quarter-end value of the position, reflecting both price change and share addition, increased by $26.46 million to $33.62 million.</p><p>GeneDx Holdings Corp. aims to deliver actionable, science-based insights to healthcare providers, supporting improved outcomes and more informed medical decision-making. Its competitive edge lies in its ability to enable precision medicine through advanced data analytics.</p><p><a href="https://www.fool.com/coverage/filings/2026/05/23/this-healthcare-investor-added-usd43-million-to-a-genomics-leader-growing-volume-34/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>The Smartest Growth Stocks to Invest $10,000 in As Investors Rotate Out of Tech</h1> <p>newsfeedback@fool.com (Reuben Gregg Brewer) — Fri, 22 May 2026 21:15:00 -0400</p> <p>When investors are in a risk-on mood, they often gravitate to growth-oriented technology stocks. When investors are in a risk-off mood, however, they often rotate out of tech and into other areas. High-yielding dividend growth stocks is one area that often sees increased interest when fear is on the rise. </p><p>Three dividend growth stocks you'll want to look at if you are considering shifting out of tech are <strong>AbbVie</strong> <span class="ticker" data-id="284305">(NYSE: ABBV)</span>, <strong>Procter & Gamble</strong> <span class="ticker" data-id="204975">(NYSE: PG)</span>, and <strong>Enterprise Products Partners</strong> <span class="ticker" data-id="207067">(NYSE: EPD)</span>. Here's why each one is worth buying and holding for the long-term.</p><p class="caption">Image source: Getty Images.</p><p><a href="https://www.fool.com/investing/2026/05/22/the-smartest-growth-stocks-to-invest-x-in-as-inves/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>ront Street Bought 384K More Shares of Enovis in Q1. Is ENOV a Buy Now?</h1> <p>newsfeedback@fool.com (Pamela Kock) — Fri, 22 May 2026 20:08:46 -0400</p> <p></p><p>According to a <a href="https://www.sec.gov/Archives/edgar/data/1683182/000168318226000003/0001683182-26-000003-index.html">Securities and Exchange Commission (SEC) filing</a> dated May 21, 2026, Front Street Capital Management purchased 384,124 additional shares of <strong>Enovis</strong><span class="ticker" data-id="208476">(NYSE:ENOV)</span>. The estimated transaction value was $9.08 million based on the average closing price during the first quarter of 2026. The quarter-end value of the Enovis stake increased by $7.33 million, reflecting both trade activity and price changes.</p><p>Enovis is a global medical technology company focused on musculoskeletal health, offering a comprehensive portfolio of orthopedic and rehabilitation products. With a diverse product range and established distribution channels, the company addresses a broad spectrum of patient needs in the healthcare sector.</p><p><a href="https://www.fool.com/coverage/filings/2026/05/22/ront-street-bought-384k-more-shares-of-enovis-in-q1-is-enov-a-buy-now/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>Is Relay Therapeutics a Buy After Promising Trial Results?</h1> <p>newsfeedback@fool.com (James Halley) — Fri, 22 May 2026 17:30:00 -0400</p> <p data-path-to-node="0" id="p-rc_a3409c8378c7bceb-26"><span class="citation-31 citation-end-31"><strong>Relay Therapeutics</strong> <span class="ticker" data-id="343580">(NASDAQ: RLAY)</span> is a clinical-stage <a href="https://www.fool.com/investing/stock-market/market-sectors/healthcare/biotech-stocks/">biotech</a> company focused on cancers and genetic diseases, using a computational platform to identify small-molecule therapies. </span><span class="citation-31 citation-end-31">Relay's stock is up more than 344% over the past year, and it jumped more than 6% in the early afternoon on May 19, the day the company announced promising results for one of its drug therapies. </span></p><p data-path-to-node="0"><span class="citation-31 citation-end-31">Relay recently presented phase 2 trial data for zovegalisib in the treatment of vascular anomalies. </span><span class="citation-31 citation-end-31">Zovegalisib works by blocking </span>PIK3CA, a gene that encodes an enzyme involved in cell growth. PIK3CA mutations are often associated with cancer. Vascular anomalies are rare disorders with abnormal development of blood vessels, lymphatic vessels, and surrounding tissues.</p><p data-path-to-node="0"><span class="citation-31 citation-end-31">The results showed that zovegalisib led to a volumetric response in about 60% of the 20 patients it evaluated. Responses were seen in PROS and lymphatic malformation patients, and across a spectrum of PIK3CA mutations. PROS is an umbrella term for a group of rare genetic disorders caused by mutations in the PIK3CA gene.</span></p><p><a href="https://www.fool.com/investing/2026/05/22/is-relay-therapeutics-a-buy-after-promising-trial/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>The Most Important Healthcare Stock You're Not Watching</h1> <p>newsfeedback@fool.com (Reuben Gregg Brewer) — Fri, 22 May 2026 17:15:00 -0400</p> <p>A company with a $140 billion market cap is very large. It is also highly likely to be an important player in the industry where it competes. But that doesn't seem to matter today for <strong>Pfizer</strong> <span class="ticker" data-id="204972">(NYSE: PFE)</span>. The healthcare giant's stock has lost more than 50% of its value since its 2021 high, seemingly forgotten by Wall Street as competitors grab headlines with their GLP-1 weight-loss drugs. Here's why Pfizer could be the most important healthcare stock you aren't watching.</p><p>To be fair, Pfizer isn't performing particularly well as a business right now. The biggest knock against the drugmaker is likely that it doesn't have a <a href="https://www.fool.com/investing/how-to-invest/stocks/glp-1-stocks/">GLP-1 weight-loss drug on the market</a>. In fact, its own internal candidate had to be dropped because it didn't meet expectations. </p><p class="caption">Image source: Getty Images.</p><p><a href="https://www.fool.com/investing/2026/05/22/the-most-important-healthcare-stock-youre-not-watc/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>Healthcare Stocks Are on Fire -- Don't Miss These Opportunities</h1> <p>newsfeedback@fool.com (Matthew Benjamin) — Fri, 22 May 2026 16:41:31 -0400</p> <p>The healthcare sector just had its best week in six months. </p><p>The <strong>State Street Health Care Select Sector SPDR ETF</strong> <span class="ticker" data-id="208775">(NYSEMKT: XLV)</span>, which tracks the healthcare sector of the <strong>S&P 500</strong> index, is up 3.3% over the past five trading sessions. That blows away the performance of the broader market -- the S&P 500 is up less than half a percentage point over the past week. And it makes healthcare the top-performing sector in the index for the week.</p><p>What's suddenly driving healthcare stocks higher?</p><p><a href="https://www.fool.com/investing/2026/05/22/healthcare-stocks-are-on-fire-dont-miss-these-oppo/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>This Healthcare Giant Is Quietly Becoming an AI Powerhouse</h1> <p>newsfeedback@fool.com (Matthew Benjamin) — Fri, 22 May 2026 13:45:00 -0400</p> <p>After a very difficult 2025, <strong>UnitedHealth Group</strong> <span class="ticker" data-id="205890">(NYSE: UNH)</span> has rebounded sharply in 2026, and artificial intelligence (AI) is a contributing factor to its recovery.</p><p><a href="https://www.fool.com/investing/stock-market/market-sectors/financials/insurance-stocks/health-insurance-stocks/">Health insurance</a> is an increasingly complex business that requires processing reams of data on benefits and claims, cost estimates, care and provider options, prescriptions, and wellness plans, among other things. And UnitedHealth is the <a href="https://www.fool.com/research/largest-healthcare-companies/">largest U.S. health insurer</a> by enrollment, with about 45 million members. It's also the largest Medicare Advantage provider in the U.S. -- it dominates Medicare Advantage coverage in 41% of the 3,200 counties in the U.S.</p><p>That extensive level of coverage means there's a lot of data to process. That suggests the <a href="https://www.fool.com/investing/stock-market/market-sectors/financials/insurance-stocks/how-insurance-companies-make-money/">health insurance </a>industry is a great sector for AI.</p><p><a href="https://www.fool.com/investing/2026/05/22/healthcare-giant-quietly-becoming-ai-stock-unh/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>What to Know About This Fund's $7 Million Bet on an AI-Focused IT Turnaround</h1> <p>newsfeedback@fool.com (Jonathan Ponciano) — Fri, 22 May 2026 10:42:03 -0400</p> <p>On May 21, 2026, Access Investment Management disclosed a new position in <strong>DXC Technology</strong> <span class="ticker" data-id="339051">(NYSE:DXC)</span>, acquiring 497,670 shares in a trade estimated at $6.68 million based on quarterly average pricing.</p><p>According to its <a href="https://www.sec.gov/Archives/edgar/data/2010477/000201047726000002/0002010477-26-000002-index.html">SEC filing</a> dated May 21, 2026, Access Investment Management reported a new position in DXC Technology, acquiring 497,670 shares during the quarter. The estimated transaction value is $6.68 million, calculated using the average unadjusted closing price for the period. The quarter-end value of the DXC position was $6.26 million, reflecting both the purchase and subsequent price movement through March 31, 2026.</p><p>DXC Technology is a global provider of information technology services that leverages its expertise in digital transformation, cloud migration, and IT outsourcing to help enterprises modernize operations and manage mission-critical systems. DXC's broad service portfolio and global reach position it as a key partner for organizations seeking to accelerate innovation and drive operational efficiency.</p><p><a href="https://www.fool.com/coverage/filings/2026/05/22/what-to-know-about-this-fund-s-usd7-million-bet-on-an-ai-focused-it-turnaround/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>Opinion: AbbVie Is the Best Dividend King to Buy in an Increasingly Uncertain Market</h1> <p>newsfeedback@fool.com (Keith Speights) — Fri, 22 May 2026 04:44:00 -0400</p> <p>Let's face it: We live in uncertain times. There's no clear end in sight to the war with Iran. Fuel prices seem likely to remain elevated for a while, likely pushing the costs of a wide range of products higher. Artificial intelligence (AI) is already disrupting some jobs. Some predict a much greater impact of AI on the job market over the next few years.</p><p>What should investors do? Buying <a href="https://www.fool.com/investing/stock-market/types-of-stocks/dividend-stocks/dividend-kings/">Dividend Kings</a>, stocks that have increased their dividends for at least 50 consecutive years, has been a pretty good strategy in the past during turbulent periods. However, choosing from the 57 stocks that qualify for the elite group could be challenging. In my opinion, one Dividend King is the best pick to buy in an increasingly uncertain market: <strong>AbbVie</strong> <span class="ticker" data-id="284305">(NYSE: ABBV)</span>.</p><p class="caption">Image source: The Motley Fool.</p><p><a href="https://www.fool.com/investing/2026/05/22/opinion-abbvie-is-the-best-dividend-king-to-buy-in/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>2 Stocks That Could Realistically Double by 2030</h1> <p>newsfeedback@fool.com (Prosper Junior Bakiny) — Fri, 22 May 2026 03:15:00 -0400</p> <p><span>The famously volatile biotech industry can help investors earn substantial returns in relatively short periods, so long as they pick the right companies. Take <strong>Abivax</strong> <span class="ticker" data-id="528507">(NASDAQ: ABVX)</span> and <strong>Viking Therapeutics</strong> <span class="ticker" data-id="335108">(NASDAQ: VKTX)</span>, two biotechs that have grown in prominence in recent years. These two drugmakers could see their shares double over the next four years -- for a compound annual growth rate of about 19% -- provided they can make significant headway with their leading pipeline candidates. Here's the rundown.</span></p><p class="caption">Image source: The Motley Fool.</p><p><span>Abivax is a clinical-stage <a href="https://www.fool.com/investing/stock-market/market-sectors/healthcare/biotech-stocks/">biotech</a> developing a promising product called obefazimod. This drug could enter the market for ulcerative colitis (UC) medicines if it earns approval. Although it is a highly competitive area, obefazimod has shown tremendous potential so far. Unlike some traditional immunosuppressants used to treat UC, which leave patients vulnerable to various infections, obefazimod does not broadly weaken the immune system.</span><span> Obefazimod aced a phase 3 clinical trial in patients with moderate-to-severe UC, about 47.3% of whom had had inadequate responses to prior therapies.</span><span> These results highlight the fact that obefazimod could be just as effective as its competitors (or even more so) while limiting side effects. That's why it looks so promising.</span></p><p><a href="https://www.fool.com/investing/2026/05/22/2-stocks-that-could-realistically-double-by-2030/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline</h1> <p>newsfeedback@fool.com (Jonathan Ponciano) — Thu, 21 May 2026 17:31:11 -0400</p> <p>B Group, Inc. disclosed a new stake in <strong>Bright Minds Biosciences</strong> <span class="ticker" data-id="452456">(NASDAQ:DRUG)</span> in its May 15, 2026, SEC filing, acquiring 67,500 shares—an estimated $5.43 million trade based on quarterly average pricing.</p><p>According to a <a href="https://www.sec.gov/Archives/edgar/data/2043476/000142050626001023/0001420506-26-001023-index.html">May 15, 2026, SEC filing</a>, B Group, Inc. initiated a new position in Bright Minds Biosciences, purchasing 67,500 shares. The estimated transaction value is $5.43 million, calculated using the average closing price for the first quarter of 2026. The value of the stake at quarter-end was $4.93 million, a figure that includes both share purchases and movement in the company’s stock price during the period.</p><p>Bright Minds Biosciences is a pre-clinical biotechnology company specializing in the development of next-generation serotonin-based therapeutics for neurological and neuropsychiatric conditions. The company leverages strategic collaborations with leading medical research institutions to accelerate innovation and expand its intellectual property portfolio. With a focus on high unmet medical needs, Bright Minds aims to establish a competitive edge through targeted drug development and scientific partnerships.</p><p><a href="https://www.fool.com/coverage/filings/2026/05/21/why-a-usd5-million-new-position-signals-confidence-in-this-epilepsy-drug-pipeline/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year</h1> <p>newsfeedback@fool.com (Jonathan Ponciano) — Thu, 21 May 2026 17:19:19 -0400</p> <p>B Group disclosed a purchase of 750,000 shares of <strong>ADMA Biologics</strong> <span class="ticker" data-id="288509">(NASDAQ:ADMA)</span> in a May 15, 2026, SEC filing, an estimated $11.84 million trade based on quarterly average pricing.</p><p>According to a <a href="https://www.sec.gov/Archives/edgar/data/2043476/000142050626001023/0001420506-26-001023-index.html">May 15, 2026, SEC filing</a>, B Group, Inc. increased its position in <strong>ADMA Biologics</strong> by 750,000 shares, with the estimated transaction value at $11.84 million based on the quarterly average price. The fund’s holding at quarter’s end stood at 3,207,542 shares, worth $28.90 million. The net position change, including share additions and price fluctuations, was a decrease of $15.93 million over the quarter.</p><p>ADMA Biologics, Inc. is a biopharmaceutical company specializing in plasma-derived therapies for immune deficiencies and infectious diseases. The company leverages a vertically integrated business model, controlling both plasma collection and product manufacturing to ensure supply chain reliability and product quality. With a focused portfolio and established distribution channels, ADMA Biologics addresses critical needs in the immunology and infectious disease markets, supporting its growth strategy and competitive positioning.</p><p><a href="https://www.fool.com/coverage/filings/2026/05/21/why-this-fund-added-usd12-million-to-a-biotech-stock-that-s-now-down-58-in-a-year/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>2 Most Compelling Stocks to Buy for Long‑Term Investors Right Now</h1> <p>newsfeedback@fool.com (Prosper Junior Bakiny) — Thu, 21 May 2026 11:30:00 -0400</p> <p><span>Even as broader equities continue to perform well, several otherwise quality stocks have been left behind due to various headwinds. That's the case with <strong>Intuitive Surgical</strong> <span class="ticker" data-id="204057">(NASDAQ: ISRG)</span> and <strong>Microsoft</strong> <span class="ticker" data-id="204577">(NASDAQ: MSFT)</span>. However, given their long-term prospects, these market leaders can bounce back and deliver excellent returns to patient investors, making them particularly compelling buys on the dip. Here is why Intuitive Surgical and Microsoft are excellent picks. </span></p><p class="caption">Image source: The Motley Fool.</p><p><span>Steep tariffs are harming Intuitive Surgical's financial results.</span><span> And by the looks of it, the company will have to deal with this issue for a little while longer. Even so, the <a href="https://www.fool.com/investing/stock-market/market-sectors/healthcare/medical-device-stocks/">medical device specialist</a> continues to post strong financial results, driven by increased adoption of its famous da Vinci system. In the first quarter, Intuitive Surgical's revenue and procedure volume both grew at a good clip. It also expanded its installed base, helping cement its lead in the robotic-assisted surgery (RAS) niche as new competitors try to eat into its market share.</span></p><p><a href="https://www.fool.com/investing/2026/05/21/2-most-compelling-stocks-to-buy-for-longterm-inves/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>How Oscar Health Is Reinventing Healthcare</h1> <p>newsfeedback@fool.com (Travis Hoium) — Thu, 21 May 2026 11:20:22 -0400</p> <p>How can <strong>Oscar Health</strong> <span class="ticker" data-id="344011">(NYSE: OSCR)</span>, a small insurer in the ACA market, upend the healthcare giants? I sat down with CEO Mark Bertolini to discuss Oscar's growth plans and how it's different from the traditional insurers. In this conversation, we cover how Oscar is playing the role of the underdog, why the network is a differentiator, and how technology plays a role in the consumer experience. </p><p><em>*Stock prices used were end-of-day prices of May 21, 2026. The video was published on May 21, 2026.</em></p><p></p><p><a href="https://www.fool.com/investing/2026/05/21/how-oscar-health-is-rethinking-healthcare/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>Is GeneDx Stock a Buys After a Company Director Purchased Over 350,000 Shares?</h1> <p>newsfeedback@fool.com (Robert Izquierdo) — Thu, 21 May 2026 10:23:01 -0400</p> <p>Board of Directors member Keith A. Meister reported the purchase of 351,273 shares of <strong>GeneDx </strong><span class="ticker" data-id="345209">(NASDAQ:WGS)</span><strong> </strong>across multiple open-market transactions from May 13 to May 15, 2026, at a weighted average price of $39.19 per share, as disclosed in this <a href="https://www.sec.gov/Archives/edgar/data/1818331/000101143826000351/0001011438-26-000351-index.htm">SEC Form 4 filing</a>.</p><p><em>Transaction and post-transaction values based on SEC Form 4 weighted average purchase price ($39.19).</em></p><p>* 1-year performance is calculated using May 15, 2026 as the reference date.</p><p><a href="https://www.fool.com/coverage/filings/2026/05/21/is-genedx-stock-a-buys-after-a-company-director-purchased-over-350-000-shares/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>Could Viking Therapeutics Be the Next Eli Lilly?</h1> <p>newsfeedback@fool.com (Adria Cimino) — Thu, 21 May 2026 08:10:00 -0400</p> <p><strong>Eli Lilly</strong> <span class="ticker" data-id="204336">(NYSE: LLY)</span> wasn't the first to conquer the weight loss drug market. <strong>Novo Nordisk</strong> started the ball rolling back in 2017, when it won approval for its GLP-1 drug, Ozempic. Though Ozempic gained approval for type 2 diabetes, doctors prescribed it off-label for weight loss, and Novo soon achieved a regulatory nod for the drug under the brand name of Wegovy, specifically for weight loss.</p><p>Though Novo continues as a giant in this market, over the past year, newer entrant Lilly has slipped into the top spot. Lilly now holds 60% of the U.S. GLP-1 weight loss drug market. But remaining the leader isn't a sure thing, as other healthcare companies, from biotechs to pharma giants, are working to enter this valuable market and potentially dominate it.</p><p>With this in mind, could <strong>Viking Therapeutics</strong> <span class="ticker" data-id="335108">(NASDAQ: VKTX)</span> be the next Eli Lilly? Let's find out.</p><p><a href="https://www.fool.com/investing/2026/05/21/could-viking-therapeutics-be-the-next-eli-lilly/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>The Most Undervalued Healthcare Stock in the S&P 500 Right Now</h1> <p>newsfeedback@fool.com (Jeff Siegel) — Thu, 21 May 2026 07:05:00 -0400</p> <p>Shares of <strong>Bristol Myers Squibb</strong> <span class="ticker" data-id="202977">(NYSE: BMY)</span> are trading in a manner that evokes little confidence in the company's future growth.</p><p>The numbers suggest otherwise. At roughly 10 times forward earnings, the drug manufacturer's stock is the cheapest among its 11 peers in the <strong>S&P 500</strong>. The measly 8% stock returns this year so far have pushed the dividend yield above 4%, the second-highest in this cohort of pharmaceuticals, trailing only <strong>Pfizer</strong>.</p><p>But here’s the kicker: at just 9.9 times trailing free cash flow (FCF), Bristol Myers Squibb is the third-cheapest of the 59 healthcare stocks in the S&P 500. That's an unusually low valuation for a pharmaceutical company expected to generate roughly $46 billion to $47.5 billion in revenue this year.</p><p><a href="https://www.fool.com/investing/2026/05/21/the-most-undervalued-healthcare-stock-in-the-sp-50/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>3 Stocks to Buy if You Think the Economy Is Heading for a Recession</h1> <p>newsfeedback@fool.com (Prosper Junior Bakiny) — Thu, 21 May 2026 02:30:00 -0400</p> <p><span>Although broader equities have performed pretty well this year, recession fears are lingering. After all, we are still dealing with macroeconomic problems and rising inflation. For those especially worried that the economy will eventually succumb to these headwinds and enter a recession, it helps to buy shares of companies that can perform well even in the most challenging environments. Here are three of them:<strong> Abbott Laboratories</strong> <span class="ticker" data-id="202702">(NYSE: ABT)</span>, <strong>Coca-Cola</strong> <span class="ticker" data-id="204186">(NYSE: KO)</span>, and <strong>Walmart</strong> <span class="ticker" data-id="206096">(NASDAQ: WMT)</span>. Read on to find out why these three stocks are excellent buys if there is a recession on the way. </span></p><p class="caption">Image source: Getty Images.</p><p><span>There are several reasons Abbott Laboratories is an excellent stock to buy ahead of a recession. First, it has a large portfolio of healthcare products across four categories: Pharmaceuticals, medical devices, nutrition, and diagnostics. Many of the products it offers remain in high demand regardless of economic conditions. For instance, in nutrition, it is a market leader in baby formula, something parents aren't going to want to stop buying, no matter what happens. Within its core <a href="https://www.fool.com/investing/stock-market/market-sectors/healthcare/medical-device-stocks/">medical device business</a>, Abbott Laboratories markets a range of products that help treat serious, sometimes life-threatening conditions. </span></p><p><a href="https://www.fool.com/investing/2026/05/21/3-stocks-to-buy-if-you-think-the-economy-is-headin/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>Best Weight Loss Drug Stocks to Buy in 2026</h1> <p>newsfeedback@fool.com (Reuben Gregg Brewer) — Wed, 20 May 2026 23:15:00 -0400</p> <p>The introduction of GLP-1 weight-loss drugs by <strong>Novo Nordisk</strong> <span class="ticker" data-id="204773">(NYSE: NVO)</span> may have changed the pharmaceutical industry forever. Although there are drawbacks to taking GLP-1 drugs (such as muscle loss), they are viewed as a miracle drug by many who have struggled for years with obesity. That said, which company is the best investment? Here are three different ways to play the space in 2026.</p><p>Novo Nordisk was first to market, but <strong>Eli Lilly</strong>'s <span class="ticker" data-id="204336">(NYSE: LLY)</span> GLP-1 shot proved more effective. And when Novo Nordisk faced production issues, the decision to choose Eli Lilly's Mounjaro and Zepbound over Novo Nordisk's Wagovy became even easier. The growth of Mounjaro and Zepbound has been nothing short of phenomenal, with Mounjaro's sales up 125% in the first quarter of 2026, and Zepbound up by 80%. </p><p class="caption">Image source: Getty Images.</p><p><a href="https://www.fool.com/investing/2026/05/20/best-weight-loss-drug-stocks-to-buy-in-2026/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>Why Phreesia Stock Got Clocked Today</h1> <p>newsfeedback@fool.com (Eric Volkman) — Wed, 20 May 2026 19:40:47 -0400</p> <p>Healthcare tech stock <strong>Phreesia</strong> <span class="ticker" data-id="341424">(NYSE: PHR)</span> could have used a pick-me-up on Wednesday. In a trading session that ended in positive territory, with the bellwether <strong>S&P 500</strong> index gaining more than 1%, Phreesia's equity lost 3.5% of its value. Much of this was directly due to an analyst's recommendation downgrade.</p><p>The responsible party was Stan Berenshteyn of "Big Four" U.S. bank <strong>Wells Fargo</strong>. Early that morning, he changed his rating on Phreesia to equal weight (hold, in other words) from his preceding overweight (buy). Accompanying that was a significant price target modification, with Berenshteyn lowering his to $9 per share from $15. </p><p class="caption">Image source: Getty Images.</p><p><a href="https://www.fool.com/investing/2026/05/20/why-phreesia-stock-got-clocked-today/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>Why Relay Therapeutics Stock Popped on Wednesday</h1> <p>newsfeedback@fool.com (Eric Volkman) — Wed, 20 May 2026 19:01:49 -0400</p> <p>One trading session after <strong>Relay Therapeutics</strong> <span class="ticker" data-id="343580">(NASDAQ: RLAY)</span> announced positive results for an investigational treatment, its shares rocketed higher on Wednesday. That rally, which saw the <a href="https://www.fool.com/investing/stock-market/market-sectors/healthcare/biotech-stocks/">biotech</a> stock rocket almost 8% higher, was aided in no small part by a pair of bullish analyst updates. </p><p>Those new analyses came on the heels of Relay's Tuesday release of Phase 2 results for zovegalisib, a drug that treats vascular anomalies. The company said that, across all doses of the medication, 60% of tested patients responded to treatment at the earliest time point of 12 weeks. </p><p class="caption">Image source: Getty Images.</p><p><a href="https://www.fool.com/investing/2026/05/20/why-relay-therapeutics-stock-popped-on-wednesday/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>Monashee Scales Back Its Bet on Structure Therapeutics</h1> <p>newsfeedback@fool.com (Pamela Kock) — Wed, 20 May 2026 15:27:07 -0400</p> <p>According to a <a href="https://www.sec.gov/Archives/edgar/data/1627608/000117266126001803/0001172661-26-001803-index.html">recent SEC filing</a> dated May 13, 2026, Monashee Investment Management reduced its holding in <strong>Structure Therapeutics</strong> <span class="ticker" data-id="482217">(NASDAQ:GPCR)</span> by 175,000 shares during the first quarter. The estimated transaction value was $11.98 million, based on the quarter’s average closing price. The value of Monashee’s GPCR position decreased by $13.24 million over the quarter, a figure that includes both trading and stock price effects.</p><p>Structure Therapeutics is a clinical-stage biotechnology company specializing in the development of novel oral therapies for chronic and serious diseases. With a focused pipeline led by GSBR-1290 for type-2 diabetes and obesity, the company leverages expertise in G-protein-coupled receptor (GPCR) drug targets to address significant market opportunities. Its strategy emphasizes innovation in small-molecule drug design, aiming to deliver differentiated treatments to large, underserved patient populations.</p><p>Monashee sharply reduced its position in Structure Therapeutics, cutting its holdings from roughly 225,000 shares to about 50,000 shares -- even as the company itself seems to be doing well. So, what does this indicate about Structure's future potential?</p><p><a href="https://www.fool.com/coverage/filings/2026/05/20/monashee-scales-back-its-bet-on-structure-therapeutics/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>My Top 3 Biotech Stocks for May 2026</h1> <p>newsfeedback@fool.com (Jeff Siegel) — Wed, 20 May 2026 11:15:00 -0400</p> <p>Biotech investors are finally getting something they haven't seen in years: a friendlier macro environment. Interest rates appear to be stabilizing, FDA activity is picking up again, and large <a href="https://www.fool.com/investing/stock-market/market-sectors/healthcare/pharmaceutical-stocks/" title="https://www.fool.com/investing/stock-market/market-sectors/healthcare/pharmaceutical-stocks/ Shift+Click to open">pharmaceutical companies</a> are sitting on billions in cash while staring down looming patent cliffs.</p><p>That combination is creating a fertile backdrop for smaller biotech companies with strong pipelines, differentiated technology, and upcoming catalysts. Here are my top three <a href="https://www.fool.com/investing/stock-market/market-sectors/healthcare/biotech-stocks/">biotech stocks</a> for May.</p><p class="caption">Image source: Getty Images.</p><p><a href="https://www.fool.com/investing/2026/05/20/my-top-3-biotech-stocks-for-may-2026/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>Why ImmunityBio Stock is Soaring Higher Today</h1> <p>newsfeedback@fool.com (Josh Kohn-Lindquist) — Wed, 20 May 2026 10:55:20 -0400</p> <p>Shares of immunotherapy biotech <strong>ImmunityBio </strong><span class="ticker" data-id="344184">(NASDAQ: IBRX)</span> initially popped today, and are up 9% as of 10:45 a.m. ET on Wednesday. After market close yesterday, ImmunityBio announced that the Food and Drug Administration (FDA) had accepted the company's supplemental biologics license application (BLA) for review, which could lead to a major label expansion for its core treatment, Anktiva.</p><p>Currently, ImmunityBio's flagship Anktiva drug is approved to treat patients with bacillus Calmette-Guérin (BCG)-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) who have Carcinoma in Situ (CIS). The new BLA would expand Anktiva's label to <span>include its use in treating BCG-unresponsive NMIBC cases <em>with papillary</em> <em>disease</em></span>, in addition to CIS. Plenty of technical terms here, but this could be a big deal for ImmunityBio, so it is worth looking into for the following reason.</p><p class="caption">Image source: Getty Images.</p><p><a href="https://www.fool.com/investing/2026/05/20/why-immunitybio-stock-soared-then-leveled-off-toda/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>CVS Health Stock Is Soaring. Could the Rally Just Be Getting Started?</h1> <p>newsfeedback@fool.com (James Halley) — Wed, 20 May 2026 08:22:00 -0400</p> <p><strong>CVS Health</strong> <span class="ticker" data-id="203253">(NYSE: CVS)</span> may just have the prescription for your investing needs if you're looking for long-term growth. The shares of the nation's largest pharmacy chain had been overlooked until recently, because of the company's thin margins and relatively slow growth.</p><p>However, over the past month, CVS stock has risen by around 24%. That's thanks to a strong first-quarter earnings report, a turnaround in its worst-performing segment, and subsequent analyst upgrades.</p><p>Here are three reasons why the rally for this <a href="https://www.fool.com/investing/stock-market/market-sectors/healthcare/">healthcare company</a> may have some legs, and one reason to still be cautious.</p><p><a href="https://www.fool.com/investing/2026/05/20/cvs-health-stock-is-soaring-could-the-rally-just-b/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>Bridge City Nearly Tripled Its Addus Position — Into a Down Stock</h1> <p>newsfeedback@fool.com (Seena Hassouna) — Tue, 19 May 2026 19:17:01 -0400</p> <p>Bridge City Capital, LLC increased its stake in <strong>Addus HomeCare</strong> <span class="ticker" data-id="223175">(NASDAQ:ADUS)</span> by 45,775 shares in the first quarter, an estimated $4.85 million trade based on quarterly average pricing, according to a May 13, 2026, SEC filing.</p><p>According to a <a href="https://www.sec.gov/Archives/edgar/data/1713521/000171352126000002/0001713521-26-000002-index.html">Securities and Exchange Commission (SEC) filing</a> dated May 13, 2026, Bridge City Capital, LLC purchased an additional 45,775 shares of Addus HomeCare during the first quarter of 2026. The estimated transaction value was $4.85 million, based on the mean unadjusted closing price for the quarter. At quarter-end, the fund’s total position in Addus HomeCare was 76,914 shares, valued at $7.20 million.</p><p>Addus HomeCare is a leading provider of home-based care solutions, leveraging a diversified service portfolio to address the needs of vulnerable populations. Its scale and focus on government and managed care payors provide resilience and recurring revenue streams. Strategic expansion and a multi-segment approach position Addus HomeCare to capture growth opportunities in the evolving healthcare landscape.</p><p><a href="https://www.fool.com/coverage/filings/2026/05/19/bridge-city-nearly-tripled-its-addus-position-into-a-down-stock/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>A beaten-down biotech just lost a meaningful backer — should you care?</h1> <p>newsfeedback@fool.com (Seena Hassouna) — Tue, 19 May 2026 17:33:01 -0400</p> <p>Bridge City Capital, LLC, fully exited its position in <strong>Harmony Biosciences Holdings</strong> <span class="ticker" data-id="343302">(NASDAQ:HRMY)</span> during the first quarter, selling 237,103 shares in a transaction estimated at $7.77 million based on quarterly average pricing, according to a May 13, 2026, SEC filing.</p><p>According to a <a href="https://www.sec.gov/Archives/edgar/data/1713521/000171352126000002/0001713521-26-000002-index.html">SEC filing</a> dated May 13, 2026, Bridge City Capital, LLC, reported selling all 237,103 shares of Harmony Biosciences Holdings during the first quarter. The estimated transaction value was $7.77 million, calculated using the average unadjusted closing price for the period. This move reduced the fund’s quarter-end position value in the company by $8.87 million, reflecting both trading and share price movements.</p><p>Harmony Biosciences Holdings, Inc. is a healthcare company focused on the biotechnology sector, specializing in treatments for rare neurological diseases. With a targeted product portfolio and a commercial focus, the company leverages its expertise to address unmet medical needs in the U.S. market. Its strategic emphasis on specialty pharmaceuticals and established relationships with healthcare professionals underpin its competitive position in the rare disease space.</p><p><a href="https://www.fool.com/coverage/filings/2026/05/19/a-beaten-down-biotech-just-lost-a-meaningful-backer-should-you-care/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>Hims & Hers Massive Stock Drop Explained</h1> <p>newsfeedback@fool.com (Travis Hoium) — Tue, 19 May 2026 14:06:34 -0400</p> <p><strong>Hims &</strong> <strong>Hers</strong> <span class="ticker" data-id="344129">(NYSE: HIMS)</span> announced the details of a $350 million debt raise today, and it will fund growth plans and add significant risk to the business. Either the debt will be converted to stock, diluting shareholders, or it will require cash to be paid back. </p><p>In this video, I explain the mechanics of the debt and capped call transaction and why Hims & Hers has limited time to prove to the market that it's a growth company again. </p><p><em>*Stock prices used were mid-day prices of May 19, 2026. The video was published on May 19, 2026.</em></p><p><a href="https://www.fool.com/investing/2026/05/19/hims-hers-10-stock-drop-explained/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares</h1> <p>newsfeedback@fool.com (Jonathan Ponciano) — Tue, 19 May 2026 13:17:19 -0400</p> <p>On May 15, 2026, Saturn V Capital Management LP disclosed in an SEC filing that it sold 822,007 shares of <strong>Dyne Therapeutics</strong> <span class="ticker" data-id="343549">(NASDAQ:DYN)</span>, an estimated $14.17 million transaction based on quarterly average pricing.</p><p>According to a <a href="https://www.sec.gov/Archives/edgar/data/1964437/000196443726000005/0001964437-26-000005-index.html">May 15, 2026, SEC filing</a>, Saturn V Capital Management sold 822,007 shares of Dyne Therapeutics during the first quarter. The estimated transaction value, based on the quarter’s average closing price, was $14.17 million. The fund finished the period with 966,609 shares, while the quarter-end value of its Dyne Therapeutics stake decreased by $17.46 million, a change that includes both sales and market price effects.</p><p>Dyne Therapeutics, Inc. is a clinical-stage biotechnology company specializing in the development of novel therapeutics for rare, genetically driven muscle diseases. The company leverages its FORCE platform to design targeted therapies with the aim of delivering disease-modifying benefits for underserved patient populations. Dyne's strategic focus on rare muscle disorders positions it to address significant unmet medical needs and build a competitive edge in the biotechnology sector.</p><p><a href="https://www.fool.com/coverage/filings/2026/05/19/dyne-therapeutics-is-up-40-but-one-biotech-fund-just-disclosed-selling-usd14-million-worth-of-shares/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors</h1> <p>newsfeedback@fool.com (Jonathan Ponciano) — Tue, 19 May 2026 13:06:23 -0400</p> <p>On May 15, 2026, Saturn V Capital Management disclosed a full exit from <strong>Ocular Therapeutix</strong> <span class="ticker" data-id="289453">(NASDAQ:OCUL)</span>, selling 1,504,880 shares in a trade estimated at $14.34 million based on quarterly average pricing.</p><p>According to an <a href="https://www.sec.gov/Archives/edgar/data/1964437/000196443726000005/0001964437-26-000005-index.html">SEC filing</a> dated May 15, 2026, Saturn V Capital Management sold its entire 1,504,880-share holding in Ocular Therapeutix. The estimated transaction value was $14.34 million, calculated using the average closing price for the first quarter of 2026. The fund's reported position in the stock fell to zero, with a quarter-end valuation shift of $18.27 million reflecting both trading and market price movement.</p><p>Ocular Therapeutix is a biopharmaceutical company with a focus on innovative drug delivery solutions for ophthalmic diseases. The company combines proprietary hydrogel technology with established and novel therapeutics, aiming to address unmet medical needs in eye care. Strategic collaborations and a diversified pipeline position Ocular Therapeutix to compete in the growing market for advanced ophthalmic therapies.</p><p><a href="https://www.fool.com/coverage/filings/2026/05/19/what-this-fund-s-usd14-million-ocular-therapeutix-exit-could-signal-for-investors/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>3 Dividend Kings to Buy and Hold for 20 Years</h1> <p>newsfeedback@fool.com (Jack Delaney) — Tue, 19 May 2026 11:30:00 -0400</p> <p>People often think about income in retirement, but anyone can benefit from buying dividend stocks, no matter where you are on your investing journey. You can collect the quarterly or monthly dividends a company pays out. Or, if you don't need the income immediately, you can set up a dividend reinvestment plan and have those payouts buy more shares.</p><p>For those looking for the utmost reliability, the <a href="https://www.fool.com/investing/stock-market/types-of-stocks/dividend-stocks/dividend-kings/">Dividend Kings</a> consistently sit at the top, achieving the rare feat of increasing their dividend payouts for 50 consecutive years or more. Three companies that have earned that title and that are worth considering holding for the next 20 years are <strong>Coca-Cola</strong> <span class="ticker" data-id="204186">(NYSE: KO)</span>, <strong>Procter & Gamble</strong> <span class="ticker" data-id="204975">(NYSE: PG)</span>, and <strong>Johnson & Johnson</strong> <span class="ticker" data-id="204142">(NYSE: JNJ)</span>.</p><p class="caption">Image source: Getty Images.</p><p><a href="https://www.fool.com/investing/2026/05/19/3-dividend-kings-to-buy-and-hold-for-20-years/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>2 Stocks That Are Much Cheaper Than They Look</h1> <p>newsfeedback@fool.com (David Jagielski, CPA) — Tue, 19 May 2026 09:30:00 -0400</p> <p>Simply looking at earnings numbers and multiples can be misleading if you're looking at stocks to buy. That's because a company can have an unusually strong or weak quarter that impacts its multiples, and in the process, it can end up looking much cheaper or more expensive than it otherwise would be. It's one of the dangers of relying solely on multiples when scanning and searching for stocks.</p><p>A couple of stocks that are much cheaper than they might initially look are <strong>AbbVie </strong><span class="ticker" data-id="284305">(NYSE: ABBV)</span> and <strong>CVS Health </strong><span class="ticker" data-id="203253">(NYSE: CVS)</span>. While at first glance these stocks may appear to be expensive and trading at high earnings multiples, a closer look reveals that they can actually end up being bargain buys. </p><p class="caption">Image source: Getty Images.</p><p><a href="https://www.fool.com/investing/2026/05/19/2-stocks-that-are-much-cheaper-than-they-look/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>Meet the Dividend King With a Higher Credit Rating Than the U.S. Government</h1> <p>newsfeedback@fool.com (Prosper Junior Bakiny) — Tue, 19 May 2026 07:30:00 -0400</p> <p><span>We live in pretty volatile times marked by macroeconomic conflicts and worsening inflation, among other things. Equity markets have fared well this year despite these challenges, but it's always a good idea to prepare for market downturns by investing in robust companies that can navigate any environment. One top stock to consider investing in right now to stabilize a well-diversified portfolio is <strong>Johnson & Johnson</strong> <span class="ticker" data-id="204142">(NYSE: JNJ)</span>, a leading healthcare player. Let's get into why the drugmaker is such an attractive pick in the current landscape. </span></p><p class="caption">Image source: The Motley Fool.</p><p><span>Several aspects of Johnson & Johnson's business make it an outstanding stock to own during a market crash, an economic downturn, or both. Let's consider three of them. First, Johnson & Johnson sells essential products that people depend on regardless of economic conditions, including <a href="https://www.fool.com/investing/stock-market/market-sectors/healthcare/pharmaceutical-stocks/">pharmaceutical</a> drugs and medical devices. No one wants to stop taking lifesaving medicines when the going gets rough. And because third-party payers help foot much of the bill for patients, many can still afford to take their meds when the purse strings tighten. Demand for the procedures that Johnson & Johnson helps physicians perform with its devices also tends to remain high across the economic cycle. </span></p><p><a href="https://www.fool.com/investing/2026/05/19/meet-the-dividend-king-with-a-higher-credit-rating/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>2 High-Yield Healthcare Stocks to Buy Before They Raise Payouts</h1> <p>newsfeedback@fool.com (Eric Volkman) — Tue, 19 May 2026 06:30:00 -0400</p> <p>It's safe to say the healthcare sector isn't renowned as a repository of dividend-paying companies.</p><p>Yet some not only pay such monies steadily and reliably, but theirs are lofty enough to be considered <a href="https://www.fool.com/investing/stock-market/types-of-stocks/dividend-stocks/high-yield-dividend-stocks/">high-yield dividends</a>. And, per their established habit, they'll surely be declaring dividend raises before long. Here's a brief look at a pair of such stocks: <strong>AbbVie</strong> <span class="ticker" data-id="284305">(NYSE: ABBV)</span> and <strong>Medtronic</strong> <span class="ticker" data-id="204416">(NYSE: MDT)</span>. </p><p class="caption">Image source: Getty Images.</p><p><a href="https://www.fool.com/investing/2026/05/19/high-yield-healthcare-stock-buy-raise-payout/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics' Pill Could Crash the Weight-Loss Party</h1> <p>newsfeedback@fool.com (Prosper Junior Bakiny) — Mon, 18 May 2026 20:45:00 -0400</p> <p><span><strong>Eli Lilly</strong> <span class="ticker" data-id="204336">(NYSE: LLY)</span> and <strong>Novo Nordisk</strong> <span class="ticker" data-id="204773">(NYSE: NVO)</span> dominate the weight-loss drug market and have for a while. What's more, recent launches are helping them expand this area and attract new patients. In January, Novo Nordisk started offering oral Wegovy, a medicine that has had tremendous success so far.</span></p><p><span> Eli Lilly recently introduced its own weight-loss pill, Foundayo, after receiving regulatory approval on April 1.</span><span> These two companies could remain leaders for a long time, but growing competition,</span><span> notably from <strong>Viking Therapeutics</strong> <span class="ticker" data-id="335108">(NASDAQ: VKTX)</span>, may weaken their hold on the market. H</span><span>ere's what investors need to know.</span></p><p class="caption">Image source: The Motley Fool.</p><p><a href="https://www.fool.com/investing/2026/05/18/watch-out-eli-lilly-and-novo-nordisk-viking-therap/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>Eli Lilly Stock: Next Stop $2,000?</h1> <p>newsfeedback@fool.com (Prosper Junior Bakiny) — Mon, 18 May 2026 18:30:00 -0400</p> <p><span>It's been a volatile year for <strong>Eli Lilly</strong> <span class="ticker" data-id="204336">(NYSE: LLY)</span>. The company's shares trended lower through the end of April, dropping well below $900. However, the drugmaker's first-quarter update, released on April 30, jolted the stock.</span><span> Eli Lilly has been on a bit of a run over the past two weeks, with its shares climbing above $1,000, as of this writing. Could the pharmaceutical leader keep the momentum going and eventually reach $2,000 per share anytime soon? </span></p><p><span>Eli Lilly's work in diabetes and weight loss is doing most of the heavy lifting right now. The company's financial results have been outstanding thanks to its dominance in the anti-obesity market. But within the next few years, more weight management medicines will enter the market. Here are several that investors should watch out for. First, <strong>Novo Nordisk</strong> -- Eli Lilly's biggest rival -- has already requested approval for its next-gen therapy, CagriSema, which could launch by the end of the year, pending approval.</span><span> Novo Nordisk is also running phase 3 studies for a candidate called Amycretin.</span><span></span></p><p class="caption">Image source: The Motley Fool.</p><p><a href="https://www.fool.com/investing/2026/05/18/eli-lilly-stock-next-stop-2000/?source=iedfolrf0000001">Continue reading</a></p> </article> <article> <h1>This Beaten-Down Growth Stock Could Soar 30%, According to Wall Street</h1> <p>newsfeedback@fool.com (Leo Sun) — Mon, 18 May 2026 16:40:00 -0400</p> <p><strong>Grail</strong> <span class="ticker" data-id="545523">(NASDAQ: GRAL)</span>, a developer of multi-cancer early detection (MCED) tests, was spun off from<strong> Illumina</strong> <span class="ticker" data-id="204015">(NASDAQ: ILMN)</span> in June 2024. Its stock started trading at $13.95 per share, set a record high of $116.06 on Jan. 22, 2026, but now trades at about $60.</p><p>Most of Grail's decline occurred in a single day in February, after its largest NHS England trial for its flagship blood test, Galleri, missed its primary endpoint. That failure drove Canaccord Genuity, which had been bullish on Grail, to reduce its Street-high price target from $105 to $80.</p><p>However, Grail's stock would still need to rise more than 30% to hit that reduced price target. Should contrarian investors take a chance on Grail's unloved stock today?</p><p><a href="https://www.fool.com/investing/2026/05/18/this-beaten-down-growth-stock-could-soar-xx-accord/?source=iedfolrf0000001">Continue reading</a></p> </article> </main></body></html>